vs
Side-by-side financial comparison of Alpha Cognition Inc. (ACOG) and AIM ImmunoTech Inc. (AIM). Click either name above to swap in a different company.
Alpha Cognition Inc. is the larger business by last-quarter revenue ($2.8M vs $21.0K, roughly 133.0× AIM ImmunoTech Inc.). Alpha Cognition Inc. runs the higher net margin — -245.5% vs -19881.0%, a 19635.5% gap on every dollar of revenue.
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
ACOG vs AIM — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $2.8M | $21.0K |
| Net Profit | $-6.9M | $-4.2M |
| Gross Margin | — | — |
| Operating Margin | -283.7% | -14057.1% |
| Net Margin | -245.5% | -19881.0% |
| Revenue YoY | — | -53.3% |
| Net Profit YoY | — | 30.0% |
| EPS (diluted) | $-0.10 | $-6.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8M | $21.0K | ||
| Q3 25 | $2.8M | $26.0K | ||
| Q2 25 | $1.7M | $25.0K | ||
| Q1 25 | $2.9M | $16.0K | ||
| Q4 24 | — | $45.0K | ||
| Q3 24 | — | $35.0K | ||
| Q2 24 | — | $50.0K | ||
| Q1 24 | — | $40.0K |
| Q4 25 | $-6.9M | $-4.2M | ||
| Q3 25 | $-1.3M | $-3.3M | ||
| Q2 25 | $-10.5M | $-2.8M | ||
| Q1 25 | $-2.0M | $-3.7M | ||
| Q4 24 | — | $-6.0M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-5.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 96.7% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -283.7% | -14057.1% | ||
| Q3 25 | -187.0% | -9411.5% | ||
| Q2 25 | -346.1% | -10584.0% | ||
| Q1 25 | -125.9% | -22618.8% | ||
| Q4 24 | — | -13011.1% | ||
| Q3 24 | — | -12825.7% | ||
| Q2 24 | — | -7388.0% | ||
| Q1 24 | — | -14335.0% |
| Q4 25 | -245.5% | -19881.0% | ||
| Q3 25 | -46.4% | -12630.8% | ||
| Q2 25 | -632.7% | -11176.0% | ||
| Q1 25 | -68.5% | -23156.3% | ||
| Q4 24 | — | -13260.0% | ||
| Q3 24 | — | -10571.4% | ||
| Q2 24 | — | -3672.0% | ||
| Q1 24 | — | -14542.5% |
| Q4 25 | $-0.10 | $-6.46 | ||
| Q3 25 | $-0.30 | $1.57 | ||
| Q2 25 | $-0.65 | $-3.68 | ||
| Q1 25 | $-0.13 | $-0.05 | ||
| Q4 24 | — | $-21.80 | ||
| Q3 24 | — | $-6.00 | ||
| Q2 24 | — | $-3.00 | ||
| Q1 24 | — | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.0M | $3.0M |
| Total DebtLower is stronger | — | $4.5M |
| Stockholders' EquityBook value | $62.5M | $-9.8M |
| Total Assets | $79.7M | $5.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.0M | $3.0M | ||
| Q3 25 | $35.4M | $2.4M | ||
| Q2 25 | $39.4M | $835.0K | ||
| Q1 25 | $45.5M | $2.2M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $7.2M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $10.9M |
| Q4 25 | — | $4.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $3.3M | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $3.3M |
| Q4 25 | $62.5M | $-9.8M | ||
| Q3 25 | $33.9M | $-6.1M | ||
| Q2 25 | $31.9M | $-6.5M | ||
| Q1 25 | $40.8M | $-3.9M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $6.1M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | $79.7M | $5.8M | ||
| Q3 25 | $46.3M | $5.5M | ||
| Q2 25 | $45.1M | $4.1M | ||
| Q1 25 | $48.6M | $6.2M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | — | $13.6M | ||
| Q2 24 | — | $15.7M | ||
| Q1 24 | — | $16.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 0.69× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.9M | $-2.0M |
| Free Cash FlowOCF − Capex | $-7.1M | — |
| FCF MarginFCF / Revenue | -252.6% | — |
| Capex IntensityCapex / Revenue | 5.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-20.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.9M | $-2.0M | ||
| Q3 25 | $-5.3M | $-5.1M | ||
| Q2 25 | $-6.1M | $-1.5M | ||
| Q1 25 | $-2.0M | $-2.4M | ||
| Q4 24 | — | $-4.0M | ||
| Q3 24 | — | $-3.1M | ||
| Q2 24 | — | $-3.0M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | $-7.1M | — | ||
| Q3 25 | $-5.4M | — | ||
| Q2 25 | $-6.1M | — | ||
| Q1 25 | $-2.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -252.6% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -370.9% | — | ||
| Q1 25 | -72.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 5.3% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
